Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | ABAT | P80404 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400966 | 1.00 | KDM4E (0.47) | KDM4ELOXL2CYP1A2CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL148514 | 0.98 | KDM4E (0.46) | KDM4ELOXL2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1363945 | 0.84 | TAAR1 (0.52) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL17823096 | 0.83 | TAAR1 (0.50) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL855443 | 0.82 | LOXL2 (0.46) | LOXL2PNMTTAAR1HRH3HTR2A | |
| Hydrochloric Acid SCHEMBL29567776 | 0.80 | LOXL2 (0.44) | LOXL2TAAR1HRH3HTR2ACA1 | |
| Hydrochloric Acid SCHEMBL16037704 | 0.80 | LOXL2 (0.44) | LOXL2TAAR1HRH3HTR2ACA1 | |
| SCHEMBL11244115 | 0.79 | KDM4E (0.49) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29418197 | 0.79 | CYP1A2 (0.53) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL333551 | 0.79 | CYP1A2 (0.53) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110088089-B | Benzyl amino pyridyl cyclopropane carboxylic acid, pharmaceutical composition and application thereof | 勃林格殷格翰国际有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-111848494-B | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-114539237-B | IDO inhibitor, preparation method, pharmaceutical composition and application | 中国药科大学 | 2023-05-23 | — | — | CN | disclosed |
| US-20230080054-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| US-11465989-B2 | Guanidine compounds and use thereof | ImmunoMet Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| WO-2022195522-A1 | INHIBITORS OF ANO6 AND THEIR USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022157686-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-07-28 | — | — | WO | disclosed |
| US-11352330-B2 | Phenoxymethyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-114539237-A | IDO inhibitor, preparation method, pharmaceutical composition and application | 中国药科大学 | 2022-05-27 | — | — | CN | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| WO-2003070247-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| CN-1439003-A | Arylmethylamine derivatives useful as tryptase inhibitors | AVENTIS PHARM PROD INC (US) | 2003-08-27 | — | — | CN | disclosed |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2003-08-21 | — | — | US | disclosed |
| US-20030158188-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES | 2003-08-21 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | KDM4E 3503/4885LOXL2 2941/4885CYP1A2 772/4885 |
| US-11352330-B2 | Phenoxymethyl derivatives | CNKSR1, RB1, RCOR1 | KDM4E 296/4885LOXL2 2949/4885CYP1A2 146/4885 |
| US-11465989-B2 | Guanidine compounds and use thereof | PC, TFAM, PCK2 | KDM4E 659/4885LOXL2 3557/4885CYP1A2 1528/4885 |
| US-20230080054-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ANO1, ANO2, CACYBP | KDM4E 3252/4885LOXL2 3376/4885CYP1A2 4801/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | KDM4E 1056/4885LOXL2 1225/4885CYP1A2 36/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | KDM4E 3000/4885LOXL2 262/4885CYP1A2 781/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | KDM4E 1056/4885LOXL2 1225/4885CYP1A2 36/4885 |
| US-20030158188-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, TMEM109, VIPR1 | KDM4E 3541/4885LOXL2 2931/4885CYP1A2 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.